A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

This is a 3-part phase 1-2 study in patients with anaplastic lymphoma kinase (ALK) + or other
potentially crizotinib-sensitive NSCLC who have been receiving crizotinib. Part A is a
single-arm, Phase 1, open-label, dose escalation design in patients with NSCLC who have
already been receiving crizotinib for at least 8 weeks and continue to tolerate therapy. Part
B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus
the combination of crizotinib + AT13387 at the maximum tolerated dose established in Part A.
Part C is an open-label, randomized, Phase 2, Simon's 2 stage design evaluating single agent
AT13387 or combination AT13387 + crizotinib at the MTD established in Part A in patients who
progressed on crizotinib at any time.

Inclusion Criteria:

1. Men or women 18 years of age or older

2. Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or
rearrangements potentially sensitive to crizotinib

3. Measurable disease

4. Must have been receiving or have received crizotinib

5. Have adequate cardiac, bone marrow, liver and kidney function

6. Must be willing and able to provide written informed consent and comply with the
protocol and study procedures

Exclusion Criteria:

1. Prior anti-cancer treatment with any HSP90 inhibitor

2. Have received chemotherapy, radiation therapy or other anticancer treatment other than
crizotinib within 3 weeks prior to the first dose of study drug

3. Prior malignancy other than adequately treated basal or squamous cell carcinoma of the
skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate
cancer, or have been disease-free for at least 3 years

4. Abnormal heart function

5. Presence of a life-threatening illness, medical condition, organ system dysfunction,
or other factors

6. Hypersensitivity of AT13387 or other components of the drug product

7. Treatment with an investigational drug within 3 weeks prior to the first dose of study
drug

8. Severe systemic diseases or active uncontrolled infections

9. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis
C virus or hepatitis B virus